HomeCompareARRW vs JNJ

ARRW vs JNJ: Dividend Comparison 2026

ARRW yields 11.11% · JNJ yields 3.36%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ARRW wins by $21.6K in total portfolio value
10 years
ARRW
ARRW
● Live price
11.11%
Share price
$18.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$41.7K
Annual income
$2,227.50
Full ARRW calculator →
JNJ
Johnson & Johnson
● Live price
3.36%
Share price
$147.50
Annual div
$4.96
5Y div CAGR
5.8%
Payout ratio
55%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$827.78
Full JNJ calculator →

Portfolio growth — ARRW vs JNJ

📍 ARRW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodARRWJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ARRW + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ARRW pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ARRW
Annual income on $10K today (after 15% tax)
$944.44/yr
After 10yr DRIP, annual income (after tax)
$1,893.38/yr
JNJ
Annual income on $10K today (after 15% tax)
$285.83/yr
After 10yr DRIP, annual income (after tax)
$703.61/yr
At 15% tax rate, ARRW beats the other by $1,189.76/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ARRW + JNJ for your $10,000?

ARRW: 50%JNJ: 50%
100% JNJ50/50100% ARRW
Portfolio after 10yr
$30.8K
Annual income
$1,527.64/yr
Blended yield
4.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

ARRW
No analyst data
Altman Z
-8.5
Piotroski
4/9
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
+55.1% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ARRW buys
0
JNJ buys
0
No recent congressional trades found for ARRW or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricARRWJNJ
Forward yield11.11%3.36%
Annual dividend / share$2.00$4.96
Payout ratio50%55%
1-year div growth0%4.2%
5-year div CAGR0%5.8%
Portfolio after 10y$41.7K$20.0K
Annual income after 10y$2,227.50$827.78
Total dividends collected$16.6K$5.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: ARRW vs JNJ ($10,000, DRIP)

YearARRW PortfolioARRW Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$11,811$1,111.11$10,676$355.77+$1.1KARRW
2$13,864$1,226.49$11,407$389.39+$2.5KARRW
3$16,180$1,345.52$12,198$426.53+$4.0KARRW
4$18,781$1,467.56$13,056$467.62+$5.7KARRW
5$21,687$1,591.96$13,987$513.12+$7.7KARRW
6$24,923$1,718.07$14,998$563.56+$9.9KARRW
7$28,513$1,845.28$16,098$619.52+$12.4KARRW
8$32,482$1,972.96$17,295$681.69+$15.2KARRW
9$36,856$2,100.55$18,599$750.82+$18.3KARRW
10$41,664$2,227.50$20,022$827.78+$21.6KARRW

ARRW vs JNJ: Complete Analysis 2026

ARRWStock

Arrowroot Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to identify and acquire a business focusing on the enterprise software sector. The company was incorporated in 2020 and is based in Marina Del Rey, California.

Full ARRW Calculator →

JNJHealthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →
📬

Get this ARRW vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ARRW vs SCHDARRW vs JEPIARRW vs OARRW vs KOARRW vs MAINARRW vs ABBVARRW vs MRKARRW vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.